Skip navigation

Critical Updates and a Roadmap for New and Proposed Changes

June 19-20, 2019
  • Alexandria, VA

At CBI’s Strategic Medicare Contracting Forum, you’ll benefit from the opportunity to gain insights from industry experts on the complex changes occurring within Medicare. In the midst of uncertainty and change, this event provides a deep dive into newly proposed regulations, including step therapy under Medicare Part B, closing the coverage gap, as well as shining a light on what lies ahead. Join colleagues and expert speakers to stay ahead of the curve on Medicare.

IN-DEPTH SESSIONS ON
HIGH-IMPACT ISSUES INCLUDING

  • Update from Washington on Medicare policy and
    perspective from the Hill
  • Assess the future of Medicare Part D
  • Analyze the potential impact of the IPI model on
    the various stakeholders
  • Understand how step therapy may influence
    Part B drug pricing
  • Review CMS’s proposed exceptions to the six protected
    drug classes in Medicare Part D
  • Discover coverage and payment strategies for novel and
    high cost therapies for rare diseases under Parts A and B
  • Impact of value frameworks on access to medications
  • Innovative pricing strategies & Part D channel impact
  • Examine the impact of reductions on WAC and
    authorized generics

Strategic Medicare Contracting Forum for Bio/Pharmaceutical Manufacturers

Critical Updates and a Roadmap for New and Proposed Changes

At CBI’s Strategic Medicare Contracting Forum, you’ll benefit from the opportunity to gain insights from industry experts on the complex changes occurring within Medicare. In the midst of uncertainty and change, this event provides a deep dive into newly proposed regulations, including step therapy under Medicare Part B, closing the coverage gap, as well as shining a light on what lies ahead. Join colleagues and expert speakers to stay ahead of the curve on Medicare.

IN-DEPTH SESSIONS ON
HIGH-IMPACT ISSUES INCLUDING

  • Update from Washington on Medicare policy and
    perspective from the Hill
  • Assess the future of Medicare Part D
  • Analyze the potential impact of the IPI model on
    the various stakeholders
  • Understand how step therapy may influence
    Part B drug pricing
  • Review CMS’s proposed exceptions to the six protected
    drug classes in Medicare Part D
  • Discover coverage and payment strategies for novel and
    high cost therapies for rare diseases under Parts A and B
  • Impact of value frameworks on access to medications
  • Innovative pricing strategies & Part D channel impact
  • Examine the impact of reductions on WAC and
    authorized generics